Yulai Zhou, MD, PhD
Postdoctoral AssociateAbout
Research
Publications
Featured Publications
Pathogenesis of diffuse large B cell lymphoma proteogenotypes.
Enssle JC, Häupl B, Qoku A, Wang B, Wright GW, Barrans S, Zhou Y, Care MA, Burton C, Gribbin C, Ziello J, Weirather J, Dai Y, Kizhakeyil A, Li X, Phelan JD, Kanangat S, Eckert S, Scheich S, Wolf S, Huang DW, Jakob J, Perner SP, Di Fonzo A, Pape M, Bodach M, Jahn D, Plessmann U, Staiger AM, Ott G, Berning P, Lenz G, Hodson DJ, Kuster B, Schmitz R, Urlaub H, Green MR, Melnick AM, Tooze R, Mlynarczyk C, Inghirami G, Buettner F, Staudt LM, Oellerich T. Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer Cell 2026 PMID: 42242231, DOI: 10.1016/j.ccell.2026.05.008.Peer-Reviewed Original Research
2025
Mitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway
Gao Y, Peng Y, Zhou Y, Zhu J, Fu S, Chen Y, Cai C, Han Y, Shen H, Zeng S, Mao L, Xiao Z. Mitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway. International Immunopharmacology 2025, 157: 114664. PMID: 40334626, DOI: 10.1016/j.intimp.2025.114664.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAnti-tumor immunityColorectal cancerResponse to immune checkpoint inhibitorsAssociated with worse overall survivalKaplan-Meier survival analysisProgression-free survivalTumor immune regulationMetastasis of colorectal cancerMitochondrial solute carriersMicrosatellite instabilityColorectal cancer cell linesColorectal cancer patientsCancer-related mortalityProliferation-related markersCheckpoint inhibitorsColorectal cancer progressionOverall survivalImmune infiltrationPotential therapeutic targetPrognostic markerUnfavorable prognosisColorectal cancer tissuesImmune regulationClinical cohortQKI-induced circ_0001766 inhibits colorectal cancer progression and rapamycin resistance by miR-1203/PPP1R3C/mTOR/Myc axis
Zhou Y, Gao Y, Peng Y, Cai C, Han Y, Chen Y, Deng G, Ouyang Y, Shen H, Zeng S, Du Y, Xiao Z. QKI-induced circ_0001766 inhibits colorectal cancer progression and rapamycin resistance by miR-1203/PPP1R3C/mTOR/Myc axis. Cell Death Discovery 2025, 11: 192. PMID: 40263288, PMCID: PMC12015279, DOI: 10.1038/s41420-025-02478-w.Peer-Reviewed Original ResearchCRC cell proliferationCircular RNAsCompetitive endogenous RNAColorectal cancer tissuesInhibited CRC cell proliferationColorectal cancer progressionRapamycin resistanceColorectal cancerEndogenous RNADrug resistancePhosphorylation of MycRNA-binding proteinsModulating CRC progressionRate of drug resistanceActivation of mTOR signalingCell proliferationAssociated with patient survivalPre-mRNACircRNAsQKI expressionMYC phosphorylationIntron 1MYC pathwayCRC progressionInduce apoptosisHMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancer
Gao Y, Fu S, Peng Y, Zhou Y, Zhu J, Zhang X, Cai C, Han Y, Shen H, Zeng S. HMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancer. Autophagy 2025, 21: 1556-1577. PMID: 40126194, PMCID: PMC12282998, DOI: 10.1080/15548627.2025.2477443.Peer-Reviewed Original ResearchColorectal cancer cellsColorectal cancerCancer cellsColorectal cancer tissuesColorectal cancer tissues of patientsLiquid chromatography-tandem mass spectrometryChromatography-tandem mass spectrometryFetal human colonProgression-free survivalClinical colorectal cancer tissuesFirst-line treatmentCell Counting Kit-8Cancer tissues of patientsPostoperative colorectal cancerCaspase 3Transmission electron microscopyCounting Kit-8Tissues of patientsMass spectrometryCleaved caspase 3Stable diseaseComplete responsePartial responseOverall survivalRegulation of chemoresistance
2024
FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types
Zhang X, Ma J, Chen Y, Deng X, Zhang Y, Han Y, Tan J, Deng G, Ouyang Y, Zhou Y, Cai C, Zeng S, Shen H. FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types. Molecular Therapy Oncology 2024, 32: 200895. PMID: 39583007, PMCID: PMC11584611, DOI: 10.1016/j.omton.2024.200895.Peer-Reviewed Original ResearchImmunotherapy resistanceB cellsPoor response to immunotherapyExpression of Blimp-1Cancer typesResponse to immunotherapyDifferentiation of B cellsB cell subpopulationsAssociated with poor response to immunotherapyPredicting treatment responseAffecting treatment efficacyDiverse cancer typesImmunotherapy efficacyImmunotherapy patientsTumor microenvironmentTreatment responsePlasma cellsImmunotherapyImmunosuppressive effectsBlimp-1Spatial transcriptomic analysisTreatment efficacyOvercome resistanceCancer treatmentImmunofluorescence analysisA humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses
Chupp D, Rivera C, Zhou Y, Xu Y, Ramsey P, Xu Z, Zan H, Casali P. A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses. Nature Immunology 2024, 25: 1489-1506. PMID: 38918608, PMCID: PMC11291283, DOI: 10.1038/s41590-024-01880-3.Peer-Reviewed Original ResearchConceptsB cellsImmune cell differentiationAntibody responseHumanized micePfizer-BioNTech coronavirus disease 2019T cell antigen receptor repertoireFollicular helper T cellsGerminal center B cellsHuman cord blood CD34Human thymic epithelial cellsT cell-independent antibody responsesImmune systemMarginal zone B cellsMaturation of antibody responsesMemory B cell differentiationCD34+ cellsCord blood CD34Helper T cellsT cell-dependentThymic epithelial cellsNeutralizing antibody responsesB cell differentiationHuman B cellsAntigen receptor repertoireCell differentiationNeuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer
Zhou Y, Zhang X, Gao Y, Peng Y, Liu P, Chen Y, Guo C, Deng G, Ouyang Y, Zhang Y, Han Y, Cai C, Shen H, Gao L, Zeng S. Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer. IScience 2024, 27: 110318. PMID: 39055918, PMCID: PMC11269305, DOI: 10.1016/j.isci.2024.110318.Peer-Reviewed Original ResearchNeuromedin U receptor 1Colorectal cancerCytotoxic T-lymphocyte-associated protein 4CD8+ T cell infiltrationCD8+ T cellsLymphocyte activation gene-3Improve immunotherapy outcomesT cell infiltrationComprehensive multi-omics analysisPersonalized immunotherapy strategiesPatient-derived tissuesColorectal cancer cell linesColorectal cancer treatmentImmunotherapy outcomesImmune checkpointsImmunotherapy efficacyImmunotherapy strategiesImmunotherapy responsePrognostic significanceImmune infiltrationT cellsMulti-omics analysisCell infiltrationGenetic alterationsHigh malignancy
2023
Intrinsic B cell TLR-BCR linked coengagement induces class-switched, hypermutated, neutralizing antibody responses in absence of T cells
Rivera C, Zhou Y, Chupp D, Yan H, Fisher A, Simon R, Zan H, Xu Z, Casali P. Intrinsic B cell TLR-BCR linked coengagement induces class-switched, hypermutated, neutralizing antibody responses in absence of T cells. Science Advances 2023, 9: eade8928. PMID: 37115935, PMCID: PMC10146914, DOI: 10.1126/sciadv.ade8928.Peer-Reviewed Original ResearchConceptsClass switch DNA recombinationT cell helpPlasma cell differentiationAntibody responseCell differentiationSomatic hypermutationGeneration of memory B cellsInduce neutralizing antibody responsesAbsence of T cellsMaturation of antibody responsesMemory B cellsNeutralizing antibody responsesResponse to NPDNA recombinationAnamnestic antibody responseMicrobial pathogensFlagellinT cellsB cellsClonal expansionClass switchingProtective antibodiesCoengagementCell receptorsDifferentiation
2022
Hsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer
Gao Y, Zhou Y, Wei L, Feng Z, Chen Y, Liu P, Peng Y, Huang Q, Gao L, Liu Y, Han Y, Shen H, Cai C, Zeng S. Hsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer. Frontiers In Immunology 2022, 13: 927811. PMID: 36405685, PMCID: PMC9667793, DOI: 10.3389/fimmu.2022.927811.Peer-Reviewed Original ResearchConceptsCircRNA-miRNA-mRNA networkInhibited CRC cell proliferationCircRNA-miRNA-mRNACRC cell proliferationNon-coding RNAsEndogenous RNAInhibit CRC proliferationCircular RNAsColorectal cancerCRC proliferationColorectal cancer tissuesRNA-seq levelCell linesImmunotherapeutic biomarkersNovel classCircRNA-seqTumor suppressive functionCircRNA profilesCircRNAsQuantitative real-time PCRAssociated with better survivalColorectal cancer cell linesAssociated with distant metastasisDownstream genesReal-time PCRIdentification of tumour immune infiltration-associated snoRNAs (TIIsno) for predicting prognosis and immune landscape in patients with colon cancer via a TIIsno score model
Cai C, Peng Y, Shen E, Wan R, Gao L, Gao Y, Zhou Y, Huang Q, Chen Y, Liu P, Guo C, Feng Z, Zhang X, Liu Y, Shen H, Zeng S, Han Y. Identification of tumour immune infiltration-associated snoRNAs (TIIsno) for predicting prognosis and immune landscape in patients with colon cancer via a TIIsno score model. EBioMedicine 2022, 76: 103866. PMID: 35144219, PMCID: PMC8844792, DOI: 10.1016/j.ebiom.2022.103866.Peer-Reviewed Original ResearchConceptsImmune cellsColon cancerImmune landscapeTumor microenvironmentImmune checkpoint expression levelsTumor-infiltrating immune cellsBiomarkers of immunotherapy responseCentral Universities of Central South UniversityNational Key R & D ProgramTumor-related deathColon cancer cell linesCell linesNatural Science Foundation of Hunan ProvinceImmune cell linesMSI-H patientsCentral South UniversityPrognosis of CC patientsImmunotherapy efficacyCancer cell linesImmunotherapy responseImmune scoreInfiltration levelsPredicting PrognosisScore modelCC patients
Academic Achievements & Community Involvement
Get In Touch
Contacts
Email